Swedish Orphan Biovitrum AB (publ) SOBI
This picture changes. Follow Swedish Orphan Biovitrum AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow Swedish Orphan Biovitrum AB (publ) freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 17 Jul 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Maintain the position; consider adding only after the company provides a concrete NASP resubmission timeline (including CMC remediation) and Q3 confirms sustained growth/margins.
Hold: operating momentum and raised guidance strengthen the core thesis, but the CRL (CMC/manufacturing) and the Zynlonta impairment increase risk and justify waiting for clearer resubmission timing and remediation details before adding.
Market sentiment
7/10
→
Trend: Stable
Sentiment remains positive after a clear Q2 beat-and-raise, but is tempered by higher regulatory/CMC uncertainty following the FDA CRL and a pipeline-related impairment.
Risk assessment
7/10
Dilution:
Low
Profitable with strong cash flow and facilities
Jurisdiction:
Low
Operates in stable EU/US regulatory markets
Execution:
Medium
Pipeline delivery and M&A integration required
Recent changes
- Sobi reported strong Q2 growth and improved profitability and raised full-year guidance for both growth and EBITA margin.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeAbout the company
Swedish Orphan Biovitrum (Sobi) is a global biopharma company developing and commercialising therapies for rare diseases across haematology, immunology and specialty care. The company is profitable with strong margins and is pursuing growth through launches and M&A, most recently the Arthrosi Therapeutics acquisition.
Sector:
Rare disease pharmaceuticals
Type:
Biotech
Next report
27 Oct 2026
Q3
Catalysts
27 Oct 2026
Q3 2026 report
Medium
Unknown
Gamifant: EMBRACE II initiation (H2 2026)
Medium
Unknown
Detailed REDUCE 2 data (pozdeutinurad) expected in Q4 2026
High
Horizon:
Bull case
The Q1 report (28 Apr) could confirm continued strong sales and margins.
- Positive momentum after upgraded outlook and a strong 2025.
- News flow around Tryngolza/olezarsen may support sentiment.
Bear case
Integration and financing costs from Arthrosi may weigh near term.
- Higher interest expense and net debt can pressure earnings.
- Elevated expectations increase earnings miss risk.
Signal rationale (informational)
Hold: operating momentum and raised guidance strengthen the core thesis, but the CRL (CMC/manufacturing) and the Zynlonta impairment increase risk and justify waiting for clearer resubmission timing and remediation details before adding.
Recent news
- On 2026-07-16 Sobi reported Q2 2026 with strong growth (revenue SEK 7,842m, +29% CER) and improved profitability (adjusted EBITA margin ~36%) and raised full-year guidance for both growth (mid-to-high teens % CER) and EBITA margin (mid-to-high 30s%). In the same period, the company also reported positive Phase 3 topline data (REDUCE 2) for pozdeutinurad in gout, while the FDA issued a CRL related to manufacturing/CMC for NASP and Sobi recorded an impairment related to Zynlonta following mixed Phase 3 results. The share price reacted positively to the Q2 release.
Price & valuation
Last close
SEK 441
1 week
+0.1 %
3 months
+0.6 %
12 months
+60.5 %
From 52w high
-8.0 %
From 52w low
+64.7 %
Exchange
Stockholm
Type
Biotech
Sector
Rare disease pharmaceuticals
This picture changes. Follow Swedish Orphan Biovitrum AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.